Characterization and biodistribution of under-employed gene therapy vector AAV7

J Virol. 2023 Nov 30;97(11):e0116323. doi: 10.1128/jvi.01163-23. Epub 2023 Oct 16.

Abstract

The use of adeno-associated viruses (AAVs) as gene delivery vectors has vast potential for the treatment of many severe human diseases. Over one hundred naturally existing AAV capsid variants have been described and classified into phylogenetic clades based on their sequences. AAV8, AAV9, AAVrh.10, and other intensively studied capsids have been propelled into pre-clinical and clinical use, and more recently, marketed products; however, less-studied capsids may also have desirable properties (e.g., potency differences, tissue tropism, reduced immunogenicity, etc.) that have yet to be thoroughly described. These data will help build a broader structure-function knowledge base in the field, present capsid engineering opportunities, and enable the use of novel capsids with unique properties.

Keywords: AAV; adeno-associated vectors; biodistribution; cryoelectron microscopy; gene therapy; virology.

MeSH terms

  • Capsid
  • Capsid Proteins / genetics
  • Dependovirus* / genetics
  • Genetic Therapy*
  • Genetic Vectors* / genetics
  • Humans
  • Phylogeny
  • Tissue Distribution

Substances

  • Capsid Proteins

Grants and funding